CRIS Current Research Information System

MAZZELLA, GIUSEPPE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.370
AS - Asia 7.905
EU - Europa 7.018
AF - Africa 549
SA - Sud America 405
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 3
Totale 26.265
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.300
VN - Vietnam 2.380
SG - Singapore 2.261
GB - Regno Unito 1.979
CN - Cina 1.913
IT - Italia 940
DE - Germania 938
SE - Svezia 847
HK - Hong Kong 511
RU - Federazione Russa 439
IN - India 424
UA - Ucraina 401
FR - Francia 328
IE - Irlanda 301
BR - Brasile 286
NL - Olanda 237
ZA - Sudafrica 164
EE - Estonia 160
CI - Costa d'Avorio 156
CH - Svizzera 106
KR - Corea 103
JP - Giappone 99
TG - Togo 91
FI - Finlandia 71
BG - Bulgaria 64
SC - Seychelles 61
AR - Argentina 48
JO - Giordania 44
CA - Canada 43
PL - Polonia 40
NG - Nigeria 39
GR - Grecia 35
ID - Indonesia 34
BE - Belgio 32
AT - Austria 30
EC - Ecuador 30
IR - Iran 22
ES - Italia 17
MX - Messico 17
PK - Pakistan 16
BD - Bangladesh 15
EG - Egitto 14
AU - Australia 11
LB - Libano 11
TR - Turchia 11
CZ - Repubblica Ceca 9
CO - Colombia 8
IQ - Iraq 8
LT - Lituania 8
PY - Paraguay 8
CL - Cile 7
MY - Malesia 7
PE - Perù 7
DK - Danimarca 6
PH - Filippine 6
RO - Romania 6
SA - Arabia Saudita 6
UZ - Uzbekistan 6
DZ - Algeria 5
HR - Croazia 5
IL - Israele 5
TN - Tunisia 5
VE - Venezuela 5
MA - Marocco 4
MK - Macedonia 4
NO - Norvegia 4
NZ - Nuova Zelanda 4
SI - Slovenia 4
BO - Bolivia 3
KE - Kenya 3
KW - Kuwait 3
LK - Sri Lanka 3
MM - Myanmar 3
AL - Albania 2
AO - Angola 2
AZ - Azerbaigian 2
BB - Barbados 2
DO - Repubblica Dominicana 2
EU - Europa 2
MD - Moldavia 2
PS - Palestinian Territory 2
PT - Portogallo 2
SY - Repubblica araba siriana 2
TW - Taiwan 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
BH - Bahrain 1
BW - Botswana 1
DM - Dominica 1
ET - Etiopia 1
GD - Grenada 1
GN - Guinea 1
HN - Honduras 1
KZ - Kazakistan 1
ML - Mali 1
MZ - Mozambico 1
NI - Nicaragua 1
NP - Nepal 1
RS - Serbia 1
SR - Suriname 1
Totale 26.260
Salva come PNG Salva come JPEG
Città #
Southend 1.800
Singapore 1.480
Fairfield 1.357
Ashburn 1.085
Chandler 854
Wilmington 514
Hong Kong 509
Ho Chi Minh City 502
Woodbridge 502
Houston 480
Seattle 469
Santa Clara 461
Dong Ket 439
Hanoi 422
Princeton 386
Cambridge 370
Ann Arbor 303
Dublin 299
Boardman 269
Beijing 255
Jacksonville 241
Bologna 213
Hefei 208
Nanjing 178
Westminster 177
Abidjan 156
Padova 149
Los Angeles 133
New York 116
Saint Petersburg 115
Berlin 110
Dallas 108
Tokyo 92
Buffalo 91
Lomé 91
Medford 87
Seoul 84
Bern 78
Milan 78
Jinan 76
Shenyang 74
Da Nang 68
Dearborn 67
Hebei 64
Sofia 61
Haiphong 60
San Diego 58
Changsha 55
Nanchang 54
Frankfurt am Main 53
Munich 52
Helsinki 46
Shanghai 46
Redondo Beach 45
Amman 44
Bremen 44
Ha Long 43
Quận Bình Thạnh 42
Mülheim 41
Abeokuta 39
Thái Nguyên 39
Biên Hòa 36
Florence 36
Guangzhou 35
Des Moines 34
Hải Dương 33
Tianjin 33
Bắc Ninh 31
Turin 31
São Paulo 30
Brussels 29
Falkenstein 29
Mahé 29
Zhengzhou 29
Jiaxing 28
Redwood City 28
Can Tho 25
Falls Church 25
Hangzhou 25
Ninh Bình 25
Pune 25
Redmond 25
Turku 23
Vinh 23
Yubileyny 23
Phoenix 22
Chicago 21
Haikou 21
Norwalk 21
Vũng Tàu 21
Wuhan 21
London 20
Ningbo 20
Olalla 20
Toronto 20
Xi'an 19
Kunming 18
Mountain View 18
Taizhou 18
Bắc Giang 17
Totale 17.419
Salva come PNG Salva come JPEG
Nome #
G-CSF in Peg-IFN induced neutropenia in liver transplanted patients with HCV recurrence 580
G-CSF administration is not related to PEG-IFN alfa-213 treatment duration nor response in liver transplanted patients with HCV recurrence 488
Outcomes and survival after TIPS positioning: a single center experience 383
Two cases of severe autoimmune manifestations following virological response to peginterferon alpha- 2b + ribavirin in liver transplanted patients with recurrence of chronic hepatitis C 321
Adefovir and lamivudine combination therapy is superior to ADV monotherapy for lamivudine-resistant patients with HBeAG-negative chronic hepatitis B 291
A new model for portal protein profile analysis in course of ileal intraluminal bile acid infusion using an in situ perfused rat intestine. 280
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation 265
A statistical model predicting high hepatocyte proliferation index and the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis 261
Antiinflammatory Effect of Phytosterols in Experimental Murine Colitis Model: Prevention, Induction, Remission Study 240
Clinical trial: modulation of human placental multidrug resistance proteins in cholestasis of pregnancy by ursodeoxycholic acid. 227
G-CSF administration is not related to Peg-IFN alfa-2b treatment duration nor response in liver transplanted patients with HCV recurrence. 222
Curcuma longa Extract Exerts a Myorelaxant Effect on the Ileum and Colon in a Mouse Experimental Colitis Model, Independent of the Anti-Inflammatory Effect 218
A RETROSPECTIVE STUDY ON INTRAHEPATIC CHOLESTASIS OF PREGNANCY: MARKERS OF PREMATURE DELIVERY 213
AISF position paper on liver disease and pregnancy 211
The future of dual therapy for hepatitis C virus 208
Berberine and its metabolites: Relationship between physicochemical properties and plasma levels after administration to human subjects 205
Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases. 200
Correlazione materno-fetale degli acidi biliari in corso di colestasi gravidica 196
Complete Remission of Advanced Hepatocellular Carcinoma Treated with Sorafenib and Concomitant Appearance of IgG4- related Diseases. A Case Report 193
High Doses of Ursodeoxycholic Acid Up-Regulate the Expression of Placental Breast Cancer Resistance Protein in Patients Affected by Intrahepatic Cholestasis of Pregnancy 191
Adverse effects of proton pump inhibitors. 189
Curcuma longa L. as a therapeutic agent in intestinal motility disorders. 2: Safety profile in mouse. 189
Generation of a novel antibody probe to the Apical Sodium-Dependent Bile Acid Transporter that inhibits ileal bile acid absorption 186
Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals 185
Relationship between indocyanine green retention test, decompensation and survival in patients with Child-Pugh A cirrhosis and portal hypertension 181
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals 180
Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. 177
Indocyanine green as a predictor of clinically significant portal hypertension in a prospective cohort study of patients with chronic liver disease 176
Measurement of spleen stiffness to evaluate portal hypertension and the presence of esophageal varices in patients with HCV-related cirrhosis 172
Treatment with direct acting antiviral agents-based regimen in HCV patients with advanced liver disease: Analysis of an Italian multicenter observational study 172
Long term follow-up and outcome of liver transplantation for alcoholic liver disease: a single center case-control study 172
Alisporivir for the treatment of chronic HCV 170
The impact of assisted reproductive technology and chorionicity in twin pregnancies complicated by obstetric cholestasis 167
Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: a prospective study on patients with HCV related cirrhosis. 167
Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals 164
Direct acting antivirals for the treatment of elderly patients with HCV advanced disease in the real life practice 163
Higher doses of peginterferon alpha-2b administered twice weekly improve sustained virological response in difficult-to-treat patients with chronic hepatitis C: results of a pilot randomized study 162
Size and location of spontaneous portosystemic shunts predict the risk of decompensation in cirrhotic patients 162
Severe immune thrombocytopenia after peg-interferonalpha2a, ribavirin and telaprevir treatment completion: A case report and systematic review of literature 161
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 161
Ribavirin for chronic hepatitis C: And the mystery goes on. 159
IL28 polymorphism and HCC after DAAs for chronic hepatitis C 159
Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis 157
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 154
Pharmacological modulation of MRP2 in primary biliary cirrhosis 153
Systemic fungemia and hepatic localizations of Fusarium solani in a liver transplanted patient: An emerging fungal agent. 153
Chronic NSAIDs Therapy and Upper Gastrointestinal Tract – Mechanism of Injury, Mucosal Defense, Risk Factors for Complication Development and Clinical Management 152
CMV infection and biliary tract complications are related with a poor outcome of liver transplantation for HCV-related cirrhosis 152
Colonic gallstone ileus treated with radiologically guided xtracorporeal shock wave lithotripsy followed by endoscopic extraction. 152
Efficacy of ursodeoxycholic acid administration on clinical manifestations of gallstones and gastrointestinal motility 151
Correlation between Indocyanine green retention test and esophageal varices among patients with hepatocellular carcinoma 151
Terapia cellulare in Epatologia 150
Regolazione dei trasportatori placentari degli acidi biliari MRP2, MRP3, MRP4 da parte dell’acido ursodesossicolico in corso di colestasi gravidica 149
Indocyanine green as a predictor of clinically significant portal hypertension in a prospective cohort study of patients with chronic liver disease. 149
Mathematical model predicting high hepatocyte proliferation index and risk of HCC in patients with HCV related cirrhosis: a proposal for clinical validation 149
HIGH FREE AND GLYCOCONJUGATED AND LOW TAUROCONJUGATED BA LEVELS IN SERUM ARE THE MIRROR OF INTESTINAL EVENTS AND HEPATIC UPTAKE 147
High incidence of allograft dysfunction in liver transplant patients treated with PEG-Interferon alfa-2b and Ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? 146
Spleen stiffness decrease as mirror of portal hypertension changes after successful interferon-free therapy in chronic-HCV patients 146
Spleen stiffness mirrors changes in portal hypertension after successful interferon-free therapy in chronic-hepatitis C virus patients 146
Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: Predictive role in HCC development in cirrhotic patients 145
Proton pump inhibitors in cirrhosis: tradition or evidence based practice? 145
Ductal stones recurrence after extracorporeal shock wave lithotripsy for difficult common bile duct stones: Predictive factors 144
Breath tests with stable isotopes: have they a role in liver transplantation? 142
An unusual cause of weight loss in a young Caucasian man 142
The foetal-maternal circulation of bile acids and bilirubin: effects of cholestasis and UDCA administration. 141
Safety of interferon beta treatment for chronic HCV hepatitis. 140
Noninvasive Assessment of Portal Hypertension in Advanced Chronic Liver Disease: An Update 140
Interleukin 28 polymorphisms and hepatocellular carcinoma development after direct acting antiviral therapy for chronihepatitis c 140
Spleen stiffness measurement: A useful prognostic tool in HCV patients treated with DAAs regimens 139
Spleen stiffness measurement can predict clinical complications in compensated HCV-related cirrhosis: a prospective study 139
THU-492 - Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: predictive role in hepatocellular carcinoma development in in cirrhotic patients 139
Orthotopic liver transplantation (OLT): contribution of imaging and interventional radiology in preparing the transplantation and managing complications. Part 2: post-OLT complications and their treatment. 137
Management of hepatic encephalopathy: focus on antibiotic therapy 137
Superior efficacy of twice a week administration of peginterferon alpha-2b plus ribavirin in obtaining SVR in HCV genotype 1 136
Noninvasive diagnosis of portal hypertension and esophageal varices through the identification of liver blood flow markers 136
Indocyanine green clearance (ICG) as a predictor of clinical decompensation and mortality in patients with compensated liver cirrhosis. 135
Indocyanine green clearance (ICG) as a predictor of 2-years clinical decompensation and mortality in patients with compensated liver cirrhosis 135
Small (≤3cm) Hepatocellular Carcinoma in Cirrhosis: the Role of Double Contrast Agents MR Imaging vs. Multi-Detector Row CT 134
Utility of Doppler-Ultrasound and Liver Elastography in the Evaluation of Patients with Suspected Pregnancy-Related Liver Disease 133
Persistent Fever and Abdominal Pain in a Young Woman With Budd-Chiari Syndrome 133
Mathematical model predicting high hepatocyte proliferation index and risk of HCC in patients with HCV related cirrhosis: a proposal for clinical validation 133
The foetal-maternal circulation of bile acids and bilirubin: effects of cholestasis and UDCA administration. 132
Reply 132
Chemiluminescence measurement of autotaxin activity in human serum 131
Incidence of gallstone disease in Italy: Results from a multicenter, population-based Italian study (the MICOL project). 131
Indocyanine green as a predictor of clinically significant portal hypertension in a prospective cohort study of patients with chronic liver disease 131
Orthotopic liver transplantation (OLT): contribution of diagnostic imaging and interventional radiology in preparing the transplantation and managing complications. Part 1: Indications, surgical technique, diagnostic imaging and interventional radiology before transplantation from cadaveric and living donor. 130
Effects of UDCA on the foetus-maternal circulation of bilirubin in cholestasis of pregnancy 130
Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial 130
P.09.6 IL28 POLYMORPHISM AND HCC DEVELOPMENT AFTER DAAS FOR CHRONIC HEPATITIS C 130
Indocyanine Green 15-min Retention test (ICG-r15) as a predictor of clinical decompensation in patients with compensated liver cirrhosis. 130
Indocyanine green clearance as a marker of decompensation and clinically significant portal hypertension in patients with liver cirrhosis. 129
Indocyanine green clearance as a marker of decompensation and clinically significant portal hypertension in patients with liver cirrhosis 129
Imaging Features of Microvascular Invasion in Hepatocellular Carcinoma Developed in HCV-Related Cirrhosis after Direct-Acting Antiviral Therapy. 128
THU-490 - Spleen stiffness measurement: a useful prognostic tool in HCV patients treated with DAAs regimens 128
Fatty liver in pregnancy: a narrative review of two distinct conditions 128
MRP2 is upregulated by UDCA in cholestasis of pregnancy. 127
Long-term leukocyte natural α-interferon and ribavirin treatment in hepatitis C virus recurrence after liver transplantation. 127
Indocyanine green as a predictor of clinically significant portal hypertension in a prospective cohort study of patients with chronic liver disease. 127
Indocyanine green as a predictor of clinically significant portal hypertension in a prospective cohort study of patients with chronic liver disease 127
Totale 17.226
Salva come PNG Salva come JPEG
Categoria #
all - tutte 72.722
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 72.722
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.533 0 0 0 0 0 83 46 150 243 138 111 762
2021/20223.802 325 146 205 235 332 196 88 204 138 171 1.187 575
2022/20233.493 420 491 200 468 232 273 92 177 612 85 240 203
2023/20241.004 70 162 58 121 83 243 37 52 71 60 21 26
2024/20253.863 153 684 354 240 679 179 215 96 43 332 147 741
2025/20265.615 1.995 765 784 567 1.052 452 0 0 0 0 0 0
Totale 26.692